Skip to main
CLLS
CLLS logo

Cellectis SA (CLLS)

$0.00

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Buy Cellectis SA (CLLS) Stock

About Cellectis SA (CLLS)

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Market cap$111.75M
Today's volume100.49K
Revenue (TTM)$47.63M
Avg. daily volume63.32K
EBITDA (TTM)-$45.64M
Open$1.58
Price / earnings ratio-2.45x
Today's range$1.55 - $1.65
Debt / equity93.65x
52 week range$1.1 - $2.43
5 year debt / equity57.78x
Beta (LTM)0.68x
Interest coverage-9.09x
Dividend & yield$0.00 (0.00%)
Current ratio1.67x
Ex-dividend date
Next earningsAug 5, 2025
Dividend payable date

Cellectis SA Stock Rating

What analysts recommend for CLLS stock, on a scale from 1(buy) to 5(sell).
Buy
Strong Buy 42%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 8%

Frequently Asked Questions (FAQ)

As of Jul 01, 2025, the market cap for CLLS stock is $111.75M

The current P/E ratio for CLLS stock is -2.45

The 52-week high for CLLS stock is $2.43. The current CLLS stock price $undefined is 100.00% below its 52-week high

The 52-week low for CLLS stock is $1.10. The current CLLS stock price $undefined has increased 100.00% from its 52-week low

No, the CLLS stock does not pay dividends to its shareholders

The target price for CLLS stock is $23.67 based on the average of what a group of analyst think CLLS stock could be worth at a future date. This is not a prediction by Public.com

How to buy CLLS stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in CLLS stock

    Navigate to the Explore page. Then, type CLLS into the search bar. When you see CLLS stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased CLLS stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.

Cellectis SA Stock Earnings

The value each CLLS share was expected to gain vs. the value that each CLLS share actually gained.

Cellectis SA (CLLS) reported Q1 2025 earnings per share (EPS) of -$0.17, beating estimates of -$0.23 by 26.09%. In the same quarter last year, Cellectis SA's earnings per share (EPS) was -$0.14. Cellectis SA is expected to release next earnings on 08/05/2025, with an earnings per share (EPS) estimate of -$0.15.

Buy Cellectis SA (CLLS) Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.